Back to Search
Start Over
MOLOGEN presents first anti-tumor data of the product candidate and TLR9 agonist EnanDIM[R] in a murine tumor model
- Source :
- Business Wire. September 12, 2016
- Publication Year :
- 2016
-
Abstract
- BERLIN -- The biotech company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) announced today first preliminary data on its EnanDIM ([R] ) technology in a murine tumor [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Business Wire
- Publication Type :
- News
- Accession number :
- edsgcl.463182733